A roadmap to preserving the prime years of patients diagnosed with MacTel, was published by Ophthalmology Times and written by Thomas Aaberg, Jr., explores the progression of MacTel and the utilization of CNTF via Neurotech’s ECT as a promising future treatment.

ABOUT THE AUTHOR: Thomas Aaberg, Jr., retinal surgeon at the Retina Specialists of Michigan, and the Chief Medical Officer of Neurotech Pharmaceuticals.